India, Nov. 9 -- BlossomHill Therapeutics, Inc. (BLSM), a clinical-stage biopharmaceutical company developing small-molecule cancer treatments, announced Monday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the recommended Phase 2 dose of investigational BH-30643 for patients with advanced or metastatic EGFR C797S-positive non-small cell lung cancer (NSCLC).
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. EGFR mutations can drive tumor growth, and resistance mutations such as C797S may emerge following treatment with third-generation EGFR tyrosine kinase inhibitors (TKIs), limiting the effectiveness of available targeted therapies.
BH-30643 is an investigational, oral, brain-a...